François Ravenelle

President & CEO, Innospera Pharma

Pharmaceutical development scientist turned entrepreneur with more than twenty years of experience in drug development. Trained in Physical Chemistry at McGill University, I have expertise in early-stage drug development, from discovery to phase II, but also contributed significantly to one approved NDA, providing exposure to the expectations of regulators. I have worked on a variety of drug products, from small molecules to peptides, and participated in the successful filing and execution of clinical trials while operating in virtual pharma company environments. At Inversago, led three financing rounds totaling more than US$110M from 2018 to 2022, and brought the company to an acquisition by Novo Nordisk for up to $1.075B.